ArticleFrontiers in bioengineering and biotechnology2025
Establishment of the first Chinese national standard for recombinant nuclease used as a process material in pharmaceutical manufacturing.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recombinant nuclease (RSN) is a critical raw material enzyme essential for removing host nucleic acids during the production of cell and gene therapy products. However, the lack of standardized quality evaluation methods and reference materials for RSN has resulted in poor reliability and comparability of testing results, hindering the standardized development of related industries. This study aimed to establish the first Chinese national standard for RSN activity, thereby enabling accurate and comparable quantification of enzymatic potency across laboratories and industries. Methods: High-purity candidate RSN reference materials were prepared and structurally analyzed via mass spectrometry. A robust enzymatic activity assay using herring sperm DNA as the substrate was optimized and validated in accordance with ICH Q2 (R2) guidelines. The assay's specificity, accuracy, and precision were evaluated, and a collaborative study involving three laboratories was subsequently conducted to determine the potency value. Results: The assay exhibited excellent precision (intra-lab coefficient of variation (CV) < 5%, inter-lab CV 2.01%) and accuracy (recovery rate 90-110%). The candidate reference material showed high homogeneity and stability. Collaborative testing confirmed the statistical consistency of the study results (P > 0.05), and the potency of the candidate material was determined to be 518 U/μL. Discussion: The establishment of this national standard will provide a unified reference for measuring RSN activity, enhance consistency in quality control, and support the safe development and production of biopharmaceuticals (including cell and gene therapies). This standard will serve as a critical tool for regulatory evaluation and industrial applications in China. The optimized content is consistent with the copyedited version of the article, featuring clear logic and comprehensive key information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.